FAILED TRIAL: PRECISION1 trial of nab-sirolimus in patients with solid tumors with TSC1/2 inactivating mutations to be halted as study unlikely to exceed the efficacy threshold August 27, 2024
First patient dosed in trial of MOMA-313 in patients with cancers carrying mutations in DNA repair genes August 27, 2024
Enrollment Completed in China GC/GEJ Pivotal Ph 2 Clinical Trial of Claudin18.2 CAR T (Satri-cel) August 27, 2024
Ph 1a/1b trial of OMX-040 in patients with advanced solid tumors advanced to expansion phase in kidney cancer and angiosarcoma August 27, 2024
First Solid Tumor Patient Treated with Second, Higher Dose in Ph 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease August 27, 2024
Human Research Ethics Committee (HREC) in Australia clears initiation of Ph 1 trial of MNPR-101-Lu August 27, 2024
Enrollment on track in Ph 2 part of PYNNACLE trial of rezatapopt monotherapy in TP53 Y220C & KRAS WT advanced solid tumor patients August 22, 2024
Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from Ph 2 SPARTA Trial Announced August 22, 2024
FDA granted Fast Track designation to Deltacel™ (KB-GDT-01) Gamma Delta T-cell (GDT) therapy August 22, 2024
Initial Data from Ph 1 Clinical Trial of EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 announced August 13, 2024
FDA grants “Study May Proceed” letter for the Ph 1/2 study of Silmitasertib (CX-4945) + chemo in children and young adults with R/R solid tumors August 13, 2024
IDEAYA Biosciences Announces Option and License Agreement for B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen August 7, 2024
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510 and IMM27M August 7, 2024
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline July 23, 2024
Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors July 23, 2024
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for novel ADC July 17, 2024
IND Submission to US FDA for Ph 1/2 study of Silmitasertib (CX-4945) in children and young adults with R/R solid tumors July 17, 2024